圣诺生物
(688117)
| 流通市值：19.22亿 | | | 总市值：32.50亿 |
| 流通股本：6622.14万 | | | 总股本：1.12亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 165,241,218.88 | 219,128,807.57 | 225,710,760.95 | 345,552,434.59 |
| 应收票据及应收账款 | 82,548,763.49 | 108,137,533.6 | 99,138,134.93 | 90,501,870.04 |
| 其中：应收票据 | 110,000 | 494,966.47 | - | 1,419,147.3 |
| 应收账款 | 82,438,763.49 | 107,642,567.13 | 99,138,134.93 | 89,082,722.74 |
| 应收款项融资 | 848,800 | - | 1,000,000 | - |
| 预付款项 | 6,365,044.36 | 9,026,345.78 | 9,360,786.27 | 10,539,716.28 |
| 其他应收款合计 | 10,650,394.14 | 10,266,859.91 | 15,811,243.52 | 15,632,219.93 |
| 存货 | 201,888,843.86 | 194,327,307 | 192,137,200.39 | 179,739,498.03 |
| 合同资产 | 8,314,564.49 | 7,753,988.84 | 24,225,924.68 | 13,048,018.99 |
| 一年内到期的非流动资产 | - | - | 301,631.95 | - |
| 其他流动资产 | 18,057,414.82 | 10,663,732.23 | 6,800,702.65 | 6,926,461.53 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 588,915,044.04 | 609,304,574.93 | 649,486,385.34 | 711,940,219.39 |
| 非流动资产: | | | | |
| 长期股权投资 | 21,520,685.46 | 22,627,020.39 | 29,854,881.23 | 24,381,023.62 |
| 其他权益工具投资 | 53,405,000 | 53,405,000 | 66,900,000 | 55,900,000 |
| 其他非流动金融资产 | 27,400,000 | 18,400,000 | - | - |
| 固定资产 | 212,491,820.66 | 207,677,843.24 | 202,518,711.08 | 206,385,253.56 |
| 在建工程 | 278,720,895.99 | 274,369,453.36 | 161,886,536.56 | 127,274,191.91 |
| 使用权资产 | 1,568,515.34 | 1,809,510.71 | 2,050,506.08 | 2,291,501.45 |
| 无形资产 | 35,273,355.25 | 35,478,368.56 | 35,683,381.87 | 35,888,395.18 |
| 开发支出 | 17,896,997.43 | 17,483,169.27 | 17,217,901.65 | 14,163,502.89 |
| 长期待摊费用 | 2,187,943.02 | 2,496,299.07 | 2,521,800.87 | 2,909,423.31 |
| 递延所得税资产 | 4,065,288.16 | 4,038,080.79 | 3,284,554.41 | 4,032,803.4 |
| 其他非流动资产 | 111,338,770.58 | 68,635,669.24 | 132,489,896.37 | 74,100,616.38 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 765,869,271.89 | 706,420,414.63 | 654,408,170.12 | 547,326,711.7 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,354,784,315.93 | 1,315,724,989.56 | 1,303,894,555.46 | 1,259,266,931.09 |
| 流动负债: | | | | |
| 短期借款 | 92,626,876.38 | 37,032,984.72 | 37,066,125 | 27,041,791.66 |
| 应付票据及应付账款 | 57,114,756.01 | 60,728,411.26 | 50,940,902.32 | 37,909,332.34 |
| 其中：应付票据 | 10,591,705.92 | 5,100,000 | 5,100,000 | - |
| 应付账款 | 46,523,050.09 | 55,628,411.26 | 45,840,902.32 | 37,909,332.34 |
| 合同负债 | 16,286,923.83 | 9,527,894.71 | 24,208,700.27 | 23,732,337.69 |
| 应付职工薪酬 | 8,924,529.42 | 13,948,978.06 | 10,529,009.8 | 9,011,250.19 |
| 应交税费 | 8,902,087.23 | 9,209,508.63 | 5,735,468.27 | 4,543,069.84 |
| 其他应付款合计 | 75,179,365.94 | 75,216,372.26 | 99,363,828.74 | 91,665,836.91 |
| 一年内到期的非流动负债 | 43,415,102.57 | 34,872,193.47 | 6,609,976.2 | 7,088,908.49 |
| 其他流动负债 | - | 740,519.26 | - | 1,419,147.3 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 302,449,641.38 | 241,276,862.37 | 234,454,010.6 | 202,411,674.42 |
| 非流动负债: | | | | |
| 长期借款 | 151,000,000 | 189,193,625.97 | 221,490,000 | 222,990,000 |
| 租赁负债 | 379,418.6 | 598,972.39 | 812,777.61 | 1,021,420.76 |
| 递延收益 | 4,383,442.82 | 4,559,955.92 | 4,550,242.4 | 4,894,342.28 |
| 递延所得税负债 | - | - | 959,543.38 | 999,447.95 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 155,762,861.42 | 194,352,554.28 | 227,812,563.39 | 229,905,210.99 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 458,212,502.8 | 435,629,416.65 | 462,266,573.99 | 432,316,885.41 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 112,000,000 | 112,000,000 | 112,000,000 | 112,000,000 |
| 资本公积 | 379,244,635.21 | 379,218,530.98 | 376,459,143.32 | 376,429,309.9 |
| 盈余公积 | 12,140,127.85 | 12,140,127.85 | 6,549,269.62 | 6,549,269.62 |
| 未分配利润 | 393,041,837.56 | 376,569,612.44 | 346,619,568.53 | 331,971,466.16 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 896,426,600.62 | 879,928,271.27 | 841,627,981.47 | 826,950,045.68 |
| 少数股东权益 | 145,212.51 | 167,301.64 | - | - |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 896,571,813.13 | 880,095,572.91 | 841,627,981.47 | 826,950,045.68 |
| 负债和股东权益合计 | 1,354,784,315.93 | 1,315,724,989.56 | 1,303,894,555.46 | 1,259,266,931.09 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-31 | 2023-08-18 |
| 审计意见(境内) | | 标准无保留意见 | | |